MedTrace Logo

A Community-based Intervention Among Active Drug Users in Montpellier

NCT04008927 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2022-07-22

No results posted yet for this study

Summary

The study aims to assess the effectiveness of a community-based model of HCV mass screening associated with an immediate HCV treatment on the cascade of care among active drug users (DUs) in the city of Montpellier, France.

Conditions

  • Drug Use
  • HCV Infection

Interventions

DIAGNOSTIC_TEST

HCV screening

All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.

DIAGNOSTIC_TEST

Diagnosis of hepatitis C

HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.

DRUG

HCV treatment

Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.

Sponsors & Collaborators

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • HELENE DONNADIEU-RIGOLE, MD, PhD · CHU Montpellier, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2021-09-10
Completion
2021-09-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008927 on ClinicalTrials.gov